1

Search

AstraZeneca Share Price Target 2026, 2027, 2028, 2030: Bear, Base & Bull Cases

  • Share this:

AstraZeneca (LSE: AZN) price as of 20 Nov 2026 close: £134.12.

AstraZeneca is the UK's largest listed company and one of the world's leading drugmakers, with major medicines in cancer, heart and kidney disease, respiratory illness and rare diseases. Under CEO Pascal Soriot it has transformed from a company facing patent cliffs into one of the industry's fastest-growing large pharma groups.

It is targeting $80 billion of revenue by 2030 and has reported 12 positive late-stage trial results so far this year. This article explains how AstraZeneca makes money and sets out an AstraZeneca share price target for 2027 to 2030 in pounds (£134.12 = 13,412p).

1. AstraZeneca share price target 2027–2030 at a glance

All three scenarios come from one transparent formula, explained in the method section below. Targets are for the end of each calendar year.

Year-endBear (£)Base (£)Bull (£)
2027110144169.5
2028113.5158.5191.5
2029117174216.5
2030120.5191.5244.5

The base case implies a price change of roughly 9% a year from today's £134.12 to the end of 2030, before dividends.


2. How AstraZeneca makes money

AstraZeneca's medicines fall into five main areas:

  • Oncology (cancer): the largest and fastest-growing area — Tagrisso (lung cancer), Imfinzi (immunotherapy), Lynparza (ovarian and breast cancer), Calquence (blood cancer) and Enhertu and Datroway (antibody-drug conjugates developed with Daiichi Sankyo).
  • Cardiovascular, Renal and Metabolism: Farxiga (diabetes, heart failure, kidney disease), Lokelma and newer weight-management and cardiovascular candidates.
  • Respiratory and Immunology: Fasenra, Breztri, Tezspire and Saphnelo.
  • Rare Diseases (Alexion): Ultomiris, Soliris and other treatments for rare conditions, acquired with Alexion in 2021.
  • Vaccines and Immune Therapies: including Beyfortus for RSV in infants.

Why the model works: patented medicines earn very high margins while protected, and AstraZeneca spends heavily on research — about a fifth of revenue — to replace older drugs as patents expire. Its large pipeline gives it many opportunities for new launches.

Why it matters for the targets: earnings growth depends on new launches outpacing patent losses (Farxiga and Soliris face generic or biosimilar competition), on trial results, and on drug-pricing policy in the US and China. AstraZeneca reports in US dollars, while its London shares trade in pence.

A short history: AstraZeneca was formed in 1999 by the merger of Sweden's Astra and the UK's Zeneca. In 2014 it rejected a takeover bid from Pfizer, promising to grow on its own through research — a promise it has largely kept. Its Covid-19 vaccine, developed with the University of Oxford, raised its global profile, and its 2021 purchase of Alexion added a large rare-disease business.


3. Latest results: what changed

Q3 2026ValueChange (CER)
Total revenue$16.2 billion+7%
Core EPS$2.79+19%
9-month revenue$46.9 billion+7%
9-month core EPS$8.00+14%
FY2026 core EPS guidanceLow double-digit growthReconfirmed

Third-quarter revenue rose 7% at constant exchange rates to $16.2 billion and core EPS 19% to $2.79, comfortably beating forecasts. For the first nine months, revenue was $46.9 billion and core EPS $8.00.

AstraZeneca reconfirmed its 2026 guidance for mid-to-high single-digit revenue growth and low double-digit core EPS growth, and said it remains on track for its 2030 ambition of $80 billion of revenue and 20 new medicines.


4. How we calculate the AstraZeneca share price targets

Target = projected EPS × P/E multiple. We start from the forward EPS of £8.47 implied by the current forward P/E, treat it as FY2027 EPS, and grow it at each scenario's rate for later years. Each year-end target applies a P/E multiple to that year's EPS. Read our full methodology.

  • Starting EPS: about £8.47, implied by a 15.8× forward P/E. Reported (IFRS) EPS is lower because of amortisation of acquired intangibles.
  • Bear case: EPS grows 3% a year, P/E 13×. Trial failures and price cuts slow growth; the multiple falls.
  • Base case: EPS grows 10% a year, P/E 17×. Low double-digit core EPS growth as new medicines offset patent losses; modest re-rating.
  • Bull case: EPS grows 13% a year, P/E 20×. The pipeline delivers and AstraZeneca reaches its 2030 ambition early, earning a premium.
Financial yearBear EPS (£)Base EPS (£)Bull EPS (£)
FY20278.478.478.47
FY20288.729.329.57
FY20298.9910.2510.82
FY20309.2611.2712.22

Worked example (base, 2027): £8.47 = £8.47 FY2027 EPS → × 17 = £144.

Sensitivity — 2030 base-case EPS of £11.27 at different multiples:

P/E13×17×20×
2030 price (£)146.5191.5225.5

The sensitivity table shows why the multiple matters as much as earnings: the same 2030 profit can justify very different prices depending on how much investors are willing to pay for it.


5. AstraZeneca share price in 2026: where it stands

With only weeks left in 2026, a year-end "target" is not meaningful. The stock was at £134.12 on 20 Nov 2026, within a 52-week range of 10,524p – 15,732p. The shares are about 15% below their 52-week high.


6. AstraZeneca share price target 2027: £110 – £169.5 (base £144)

Based on FY2027 EPS of £8.47 / £8.47 / £8.47 (bear / base / bull). What to watch: Late-stage trial readouts across oncology and cardiovascular drugs.


7. AstraZeneca share price target 2028: £113.5 – £191.5 (base £158.5)

Based on FY2028 EPS of £8.72 / £9.32 / £9.57 (bear / base / bull). What to watch: Sales of Enhertu, Datroway and Imfinzi.


8. AstraZeneca share price target 2029: £117 – £216.5 (base £174)

Based on FY2029 EPS of £8.99 / £10.25 / £10.82 (bear / base / bull). What to watch: Impact of generic Farxiga and biosimilar Soliris.


9. AstraZeneca share price target 2030: £120.5 – £244.5 (base £191.5)

Based on FY2030 EPS of £9.26 / £11.27 / £12.22 (bear / base / bull). What to watch: US drug pricing and tariffs on imported medicines.


10. Key metrics

AstraZeneca's forward P/E is far below its trailing P/E because reported earnings include large non-cash amortisation charges.

MetricValueWhy it matters
Forward EPS (est.)~£8.47Starting point
Trailing P/E25.2×Includes amortisation
Forward P/E15.8×Reasonable for growth
Q3 core EPS growth+19% (CER)Strong
2030 revenue ambition$80 billionLong-term target

11. Dividends and shareholder returns

AstraZeneca pays a dividend twice a year, declared in US dollars. Over the last 12 months it paid the equivalent of about £2.39 per share, a yield of roughly 1.8%. The company prioritises reinvestment in research and manufacturing, so it does not run large buybacks.

The dividend has been stable to rising, and management has said it aims to grow it over time as earnings grow.


12. How it compares with other FTSE 100 leaders

CompanyPriceTrailing P/EForward P/EDividend yield52-week range
AstraZeneca (AZN)13,412p25.2×15.8×1.8%10,524p – 15,732p
Barclays (BARC)397.25p8.0×6.6×2.2%361.40p – 554.10p
BAE Systems (BA.)1,814p26.0×20.2×2.1%1,529p – 2,360p
Unilever (ULVR)4,887.50p13.4×17.3×3.5%3,644p – 5,542p
Rio Tinto (RIO)5,640p10.1×9.1×5.3%5,182p – 9,117p

Prices as of 20 Nov 2026 close (LSE). The companies are in different sectors, so the table is a valuation snapshot. See also our HSBC, Lloyds and Rolls-Royce targets.


13. The key debate on AstraZeneca

The bull argument: AstraZeneca has one of the deepest pipelines in the industry, a strong cancer franchise and a clear path to $80 billion of revenue by 2030. Core EPS is growing in the teens, yet the stock trades at only about 16× forward earnings.

The bear argument: Several big drugs face patent expiry, US pricing reform could cut margins, and the company has heavy exposure to China, where it has faced investigations. Trial failures can quickly change the outlook.

How to tell which side is winning: Watch core EPS growth and pipeline readouts. Continued double-digit growth with positive trials supports the bull case; a string of failures or US price cuts would point to the bear case.


14. Risks that would break the base case

  • Clinical trial failures in key pipeline drugs.
  • US drug-pricing reforms and possible tariffs.
  • Generic and biosimilar competition for older medicines.
  • Regulatory and legal issues in China.
  • Currency swings between the dollar and the pound.

15. What the numbers suggest

Our base case of £191.5 by 2030 assumes 10% annual core EPS growth and a modest re-rating to 17×. The bear case (£120.5) reflects pipeline setbacks; the bull case (£244.5) assumes AstraZeneca delivers its 2030 ambition with room to spare.

Who might consider AstraZeneca: long-term investors seeking exposure to innovative medicines and steady earnings growth, who can accept that individual trial results will move the shares.

This is a framework, not a recommendation. Your own decision should depend on your time horizon, risk tolerance and existing holdings.


16. FAQs on the AstraZeneca share price

What is the AstraZeneca share price target for 2027?
Our base case is £144, assuming 10% annual EPS growth and a 17× P/E. The range is £110 (bear) to £169.5 (bull).

What is the AstraZeneca share price target for 2030?
Base case £191.5; range £120.5 to £244.5. It assumes FY2030 EPS of about £11.27.

Is AstraZeneca listed in London?
Yes, its primary listing is on the LSE (AZN). It also trades in Stockholm and New York.

Does AstraZeneca pay a dividend?
Yes, twice a year, worth about £2.39 per share over the last 12 months — a yield of around 1.8%.

What is AstraZeneca's 2030 ambition?
To reach $80 billion of total revenue and launch 20 new medicines by 2030.

Why are targets shown in pounds?
UK shares trade in pence. £134.12 equals 13,412p.

Who is AstraZeneca's CEO?
Pascal Soriot, who has led the company since 2012.

About this analysis: Prepared by the ChartMyWealth Editorial Team using the scenario method described in our methodology. Prices and results were reviewed on 20 Nov 2026, and targets are reviewed after each results announcement.

Disclaimer: This article is for educational purposes only and is not investment advice or a recommendation to buy or sell any security. Price targets are scenario estimates based on the stated assumptions and may not materialise. Please consult an FCA-authorised financial adviser before making investment decisions.

ChartMyWealth Editorial Team

ChartMyWealth Editorial Team

The ChartMyWealth Editorial Team analyses Indian and US listed companies using their reported results, exchange filings and market data. Every share price target shows its formula, assumptions and sources, with bear, base and bull scenarios, and is updated after quarterly results.

Leave a comment

Your email address will not be published. Required fields are marked *

Your experience on this site will be improved by allowing cookies. Cookie Policy